111 related articles for article (PubMed ID: 30713338)
1. Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?
Nichetti F; Falvella FS; Miceli R; Cheli S; Gaetano R; Fucà G; Infante G; Martinetti A; Antoniotti C; Falcone A; Di Bartolomeo M; Cremolini C; de Braud F; Pietrantonio F
Pharmacogenomics J; 2019 Oct; 19(5):465-472. PubMed ID: 30713338
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study.
Custodio A; Moreno-Rubio J; Aparicio J; Gallego-Plazas J; Yaya R; Maurel J; Higuera O; Burgos E; Ramos D; Calatrava A; Andrada E; López R; Moreno V; Madero R; Cejas P; Feliu J
Ann Oncol; 2014 Feb; 25(2):398-403. PubMed ID: 24351404
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms associated with oxaliplatin-induced peripheral neurotoxicity in Japanese patients with colorectal cancer.
Oguri T; Mitsuma A; Inada-Inoue M; Morita S; Shibata T; Shimokata T; Sugishita M; Nakayama G; Uehara K; Hasegawa Y; Ando Y
Int J Clin Pharmacol Ther; 2013 Jun; 51(6):475-81. PubMed ID: 23547850
[TBL] [Abstract][Full Text] [Related]
4. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study.
Argyriou AA; Cavaletti G; Antonacopoulou A; Genazzani AA; Briani C; Bruna J; Terrazzino S; Velasco R; Alberti P; Campagnolo M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Psaromyalou A; Angelopoulou A; Kalofonos HP
Cancer; 2013 Oct; 119(19):3570-7. PubMed ID: 23821303
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
6. Neurotoxicity Outcomes in a Population-based Cohort of Elderly Patients Treated With Adjuvant Oxaliplatin for Colorectal Cancer.
Raphael MJ; Fischer HD; Fung K; Austin PC; Anderson GM; Booth CM; Singh S
Clin Colorectal Cancer; 2017 Dec; 16(4):397-404.e1. PubMed ID: 28434884
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin rechallenge in metastatic colorectal cancer patients with clinically significant oxaliplatin-induced peripheral neurotoxicity.
Argyriou AA; Kalofonou F; Litsardopoulos P; Anastopoulou GG; Kalofonos HP
J Peripher Nerv Syst; 2021 Mar; 26(1):43-48. PubMed ID: 33345432
[TBL] [Abstract][Full Text] [Related]
8. Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve.
Alberti P; Rossi E; Argyriou AA; Kalofonos HP; Briani C; Cacciavillani M; Campagnolo M; Bruna J; Velasco R; Cazzaniga ME; Cortinovis D; Valsecchi MG; Cavaletti G
Support Care Cancer; 2018 Sep; 26(9):3143-3151. PubMed ID: 29594485
[TBL] [Abstract][Full Text] [Related]
9. DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.
Falvella FS; Cheli S; Martinetti A; Mazzali C; Iacovelli R; Maggi C; Gariboldi M; Pierotti MA; Di Bartolomeo M; Sottotetti E; Mennitto R; Bossi I; de Braud F; Clementi E; Pietrantonio F
Br J Clin Pharmacol; 2015 Sep; 80(3):581-8. PubMed ID: 25782327
[TBL] [Abstract][Full Text] [Related]
10. Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis.
Terrazzino S; Argyriou AA; Cargnin S; Antonacopoulou AG; Briani C; Bruna J; Velasco R; Alberti P; Campagnolo M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Kalofonos HP; Canonico PL; Genazzani AA; Cavaletti G
J Peripher Nerv Syst; 2015 Mar; 20(1):15-23. PubMed ID: 25858589
[TBL] [Abstract][Full Text] [Related]
11. Liability of the voltage-gated potassium channel KCNN3 repeat polymorphism to acute oxaliplatin-induced peripheral neurotoxicity.
Argyriou AA; Antonacopoulou AG; Alberti P; Briani C; Bruna J; Velasco R; Anastopoulou GG; Park SB; Cavaletti G; Kalofonos HP
J Peripher Nerv Syst; 2019 Dec; 24(4):298-303. PubMed ID: 31486252
[TBL] [Abstract][Full Text] [Related]
12. Early Neuropathy Related to Oxaliplatin Treatment in Advanced and Recurrent Colorectal Cancer.
Nagata T; Fukuda KI; Tamai M; Taniguchi A; Kamiya H; Kambe K; Kamada Y; Iwata G; Yamaoka N
Anticancer Res; 2019 Mar; 39(3):1347-1353. PubMed ID: 30842168
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.
Zarate R; Rodríguez J; Bandres E; Patiño-Garcia A; Ponz-Sarvise M; Viudez A; Ramirez N; Bitarte N; Chopitea A; Gacía-Foncillas J
Br J Cancer; 2010 Mar; 102(6):987-94. PubMed ID: 20216541
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms in cyclin H gene are associated with oxaliplatin-induced acute peripheral neuropathy in South Indian digestive tract cancer patients.
Palugulla S; Devaraju P; Kayal S; Narayan SK; Mathaiyan J
Cancer Chemother Pharmacol; 2018 Sep; 82(3):421-428. PubMed ID: 29936608
[TBL] [Abstract][Full Text] [Related]
15. Is quantitative sensory testing helpful in the management of oxaliplatin neuropathy? a two-year clinical study.
Delmotte JB; Beaussier H; Auzeil N; Massicot F; Laprévote O; Raymond E; Coudoré F
Cancer Treat Res Commun; 2018; 17():31-36. PubMed ID: 30343217
[TBL] [Abstract][Full Text] [Related]
16. ABCB1 c.3435C>T polymorphism is associated with platinum toxicity: a preliminary study.
De Troia B; Dalu D; Filipazzi V; Isabella L; Tosca N; Ferrario S; Gambaro AR; Somma L; Fasola C; Cheli S; Clementi E; De Francesco D; Falvella FS; Cattaneo MT
Cancer Chemother Pharmacol; 2019 Apr; 83(4):803-808. PubMed ID: 30796464
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin-induced peripheral neuropathy risk factors and management in Tunisian population.
Zribi A; Nasr SB; Hamdi S; Ayari J; Fendri S; Balti M; Haddaoui A
Pan Afr Med J; 2020; 35():83. PubMed ID: 32537086
[TBL] [Abstract][Full Text] [Related]
18. Skin platinum deposition in colorectal cancer patients following oxaliplatin-based therapy.
Cao Y; Chang Q; Zhang W; Ornatsky O; Hedley D; Chen EX
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1195-1200. PubMed ID: 31520102
[TBL] [Abstract][Full Text] [Related]
19. SNPs in transporter and metabolizing genes as predictive markers for oxaliplatin treatment in colorectal cancer patients.
Kap EJ; Seibold P; Scherer D; Habermann N; Balavarca Y; Jansen L; Zucknick M; Becker N; Hoffmeister M; Ulrich A; Benner A; Ulrich CM; Burwinkel B; Brenner H; Chang-Claude J
Int J Cancer; 2016 Jun; 138(12):2993-3001. PubMed ID: 26835885
[TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin-Induced Neuropathy: A Long-Term Clinical and Neurophysiologic Follow-Up Study.
Kokotis P; Schmelz M; Kostouros E; Karandreas N; Dimopoulos MA
Clin Colorectal Cancer; 2016 Sep; 15(3):e133-40. PubMed ID: 27038553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
